Research
We are devoted to providing the very best care and treatment for the children and adolescents with cancer and blood disorders. To do so, we adopt the newest and most effective treatments currently available while we work continuously and actively towards innovations and improvements. As a result, we have established ourselves as a force of excellence at the forefront of clinical research and development in the field of childhood cancer and blood disorders.
Providing access to clinical trials worldwide
As a vital element of our comprehensive, child-centered approach, CHAM offers our patients access to the latest, most promising clinical trials. New treatments for childhood cancer and blood disorders are being developed constantly, and clinical trials allow our patients to be among the first to try pioneering treatment agents and concepts.
CHAM is an active member of the Children’s Oncology Group (COG), an international consortium of pediatric cancer centers dedicated to advancing treatment for children with cancer by combining global resources and expertise for clinical trials. Our patients benefit from access to all the latest national and international trials, through CHAM, COG and the National Institutes of Health.
We participate in the Dana Farber Cancer Institute’s Acute Lymphoblastic Leukemia Consortium, with access to their clinical trials. We also participate in industry-sponsored and NIH-supported investigator-initiated clinical trials
Bringing research from the laboratory to the bedside
At CHAM, we are dedicated to actively pursuing new areas of research right here at Montefiore by developing our own treatment agents and therapies. We confront highly aggressive forms of pediatric cancer and blood disease with an equally aggressive push toward advancing the field of research and development. Our passionate, proactive approach includes pioneering our own agents and treatment concepts that can be tested in clinical trials.
Leading the fight against childhood disease
Among other areas of clinical research, CHAM is currently involved in cutting-edge clinical trials for our patients with leukemia, focusing specifically on reducing the toxic side effects of curative therapy. In pediatric neuro-oncology, we have developed innovative monitoring equipment and are working on software that will increase the safety and accuracy of the very delicate surgery required to treat brain tumors.We are currently focused on a new trial of chemotherapy for a rare form of brain tumor (ATRT).
We have gained a national reputation as a groundbreaking center of study on sickle cell disease. CHAM has participated in stroke prevention trials and has participated in efforts to test the efficacy of hydroxyurea. In addition, we have been awarded an NIH grant to study the role of genetics, screening sickle cell patients for risk of stroke.
In all areas of applicable research, CHAM is a key player in the ultimate fight — to one day eradicate childhood cancer and blood disease entirely.
Below is a listing of current clinical trials in Childhood Cancers and Blood Disorders